Emergent Biosolutions Inc (EBS) - Total Assets
Based on the latest financial reports, Emergent Biosolutions Inc (EBS) holds total assets worth $1.12 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Emergent Biosolutions Inc - Total Assets Trend (2001–2025)
This chart illustrates how Emergent Biosolutions Inc's total assets have evolved over time, based on quarterly financial data. Also see Emergent Biosolutions Inc stock valuation for the company's overall valuation and market capitalisation.
Emergent Biosolutions Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Emergent Biosolutions Inc's total assets of $1.12 Billion consist of 50.2% current assets and 49.8% non-current assets. Review EBS liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $205.40 Million | 15.6% |
| Accounts Receivable | $84.20 Million | 6.4% |
| Inventory | $343.40 Million | 26.0% |
| Property, Plant & Equipment | $216.00 Million | 16.4% |
| Intangible Assets | $436.50 Million | 33.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Emergent Biosolutions Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See EBS share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Emergent Biosolutions Inc's current assets represent 50.2% of total assets in 2025, a decrease from 4704.0% in 2001.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, down from 23.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 3657.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 33.1% of total assets.
Emergent Biosolutions Inc Competitors by Total Assets
Key competitors of Emergent Biosolutions Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs179.65 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Emergent Biosolutions Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.42 | 5.66 | 2.94 |
| Quick Ratio | 2.95 | 3.00 | 1.94 |
| Cash Ratio | 0.00 | 2.10 | 1.11 |
| Working Capital | $543.20 Million | $592.40 Million | $708.10 Million |
Emergent Biosolutions Inc - Advanced Valuation Insights
This section examines the relationship between Emergent Biosolutions Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | $1.32 Billion |
| Market Capitalization | $228.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Emergent Biosolutions Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Emergent Biosolutions Inc's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Emergent Biosolutions Inc (2001–2025)
The table below shows the annual total assets of Emergent Biosolutions Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.32 Billion | -5.12% |
| 2024-12-31 | $1.39 Billion | -23.78% |
| 2023-12-31 | $1.82 Billion | -42.42% |
| 2022-12-31 | $3.17 Billion | +7.05% |
| 2021-12-31 | $2.96 Billion | +2.58% |
| 2020-12-31 | $2.88 Billion | +23.89% |
| 2019-12-31 | $2.33 Billion | +4.39% |
| 2018-12-31 | $2.23 Billion | +108.32% |
| 2017-12-31 | $1.07 Billion | +10.32% |
| 2016-12-31 | $970.11 Million | -7.04% |
| 2015-12-31 | $1.04 Billion | +10.40% |
| 2014-12-31 | $945.26 Million | +50.85% |
| 2013-12-31 | $626.63 Million | +11.06% |
| 2012-12-31 | $564.23 Million | +3.18% |
| 2011-12-31 | $546.86 Million | +9.30% |
| 2010-12-31 | $500.32 Million | +45.15% |
| 2009-12-31 | $344.69 Million | +18.54% |
| 2008-12-31 | $290.79 Million | +6.32% |
| 2007-12-31 | $273.51 Million | +14.80% |
| 2006-12-31 | $238.25 Million | +137.47% |
| 2005-12-31 | $100.33 Million | +45.29% |
| 2004-12-31 | $69.06 Million | +203.01% |
| 2002-12-31 | $22.79 Million | -10.36% |
| 2001-12-31 | $25.42 Million | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more